Puma Biotechnology (PBYI) FCF Margin (2017 - 2026)

Puma Biotechnology has reported FCF Margin for 10 years, with the latest figure at 34.36% in Q1 2026.

• For the quarter ending Q1 2026, FCF Margin rose 2665.0% year-over-year to 34.36%; the trailing twelve-month figure through Mar 2026 stood at 23.61% (up 1020.0% YoY), and the FY2025 full-year result was 18.3%, up 141.0% from the prior year.
• FCF Margin for Q1 2026 stood at 34.36%, up from 19.24% in the prior quarter.
• The five-year high for FCF Margin was 34.36% in Q1 2026, with the low at 58.8% in Q1 2022.
• Historically, FCF Margin has averaged 10.05% across 5 years, with a median of 16.75% in 2022.
• Annual changes were most pronounced in 2022 — FCF Margin slumped 7476 bps — and 2023, when it surged 6381 bps.
• Puma Biotechnology's FCF Margin stood at 16.75% in 2022, then fell by 13 bps to 14.58% in 2023, then soared by 81 bps to 26.45% in 2024, then declined by 27 bps to 19.24% in 2025, then soared by 79 bps to 34.36% in 2026.
• The last three FCF Margin figures came in at 34.36% (Q1 2026), 19.24% (Q4 2025), and 17.74% (Q3 2025), per Business Quant data.